Immuron (IMRN) has released an update.
Immuron Limited, an Australian biopharmaceutical company, is set to host a webinar with CEO Steven Lydeamore to discuss its advancements in orally delivered targeted polyclonal antibodies for infectious diseases. Their product Travelan® is designed to reduce the risk of travelers’ diarrhea and is available in various global markets. The company also highlights its ongoing development of IMM-529, aimed at treating Clostridioides difficile infections.
For further insights into IMRN stock, check out TipRanks’ Stock Analysis page.
